Table 3A Adverse events occurring in at least 10% of patients

From: Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

 

Grade of adverse event

 

Adverse event

1

2

3

4

Total number (%) of patients a

Nausea

14

2

2

0

18 (40.9)

Fatigue

12

5

1

0

18 (40.9)

Rash

10

3

1

0

14 (31.8)

Pyrexia

9

2

0

0

11 (25.0)

Chills

9

0

1

0

10 (22.7)

Decreased appetite

8

2

0

0

10 (22.7)

Vomiting

8

2

0

0

10 (22.7)

Anaemia

1

4

4

0

9 (20.5)

Infusion-related reaction

2

4

2

0

8 (18.2)

Dyspnoea

3

3

0

1

7 (15.9)

Constipation

7

0

0

0

7 (15.9)

Abdominal pain

4

0

3

0

7 (15.9)

Dyspepsia

5

2

0

0

7 (15.9)

GGT increased

0

1

5

0

6 (13.6)

Urinary tract infection

2

2

2

0

6 (13.6)

Blood creatinine increased

1

5

0

0

6 (13.6)

Pruritus

5

1

0

0

6 (13.6)

AST increased

0

1

4

0

5 (11.4)

Hyperglycaemia

0

3

2

0

5 (11.4)

Arthralgia

2

3

0

0

5 (11.4)

Cough

5

0

0

0

5 (11.4)

  1. Abbreviations: AST=aspartate aminotransferase; GGT=γ-glutamyl transferase.
  2. aNumber and percentage of patients experiencing at least one event during the course of the study are reported at the highest grade experienced.
Back to article page